GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » H. Lundbeck AS (LTS:0ND5) » Definitions » 3-Year ROIIC %

H. Lundbeck AS (LTS:0ND5) 3-Year ROIIC % : -18.92% (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is H. Lundbeck AS 3-Year ROIIC %?

3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year. H. Lundbeck AS's 3-Year ROIIC % for the quarter that ended in Dec. 2023 was -18.92%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for H. Lundbeck AS's 3-Year ROIIC % or its related term are showing as below:

LTS:0ND5's 3-Year ROIIC % is ranked worse than
70.82% of 1028 companies
in the Drug Manufacturers industry
Industry Median: 0.37 vs LTS:0ND5: -18.92

H. Lundbeck AS 3-Year ROIIC % Historical Data

The historical data trend for H. Lundbeck AS's 3-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

H. Lundbeck AS 3-Year ROIIC % Chart

H. Lundbeck AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
3-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.99 -5.94 -12.91 7.77 -18.92

H. Lundbeck AS Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
3-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -18.92 -

Competitive Comparison of H. Lundbeck AS's 3-Year ROIIC %

For the Drug Manufacturers - Specialty & Generic subindustry, H. Lundbeck AS's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


H. Lundbeck AS's 3-Year ROIIC % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, H. Lundbeck AS's 3-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where H. Lundbeck AS's 3-Year ROIIC % falls into.



H. Lundbeck AS 3-Year ROIIC % Calculation

H. Lundbeck AS's 3-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

3-Year ROIIC %=3-Year Incremental Net Operating Profit After Taxes (NOPAT)**/3-Year Incremental Invested Capital**
=( 2444.4945 (Dec. 2023) - 1650.705 (Dec. 2020) )/( 25479 (Dec. 2023) - 29675 (Dec. 2020) )
=793.7895/-4196
=-18.92%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


H. Lundbeck AS  (LTS:0ND5) 3-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


H. Lundbeck AS 3-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of H. Lundbeck AS's 3-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


H. Lundbeck AS (LTS:0ND5) Business Description

Address
Ottiliavej 9, Valby, DNK, 2500
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system, or CNS, drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.

H. Lundbeck AS (LTS:0ND5) Headlines

No Headlines